Pain

Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes

By Pietro Falco, Alessandra Di Flaviani, Eleonora Galosi, Andrea Truini

Cross-sectional study of 500 peopleInterventions

The paper

Pietro Falco, Alessandra Di Flaviani, Eleonora Galosi, Andrea Truini

Sapienza University of Rome

Pain, 20 Aug 2026

doi.org/10.1097/j.pain.0000000000004104 PubMed 42663556

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes